Proactive Investors - Run By Investors For Investors

Silence Therapeutics finance chief departs

Silence’s group head of financial planning and analysis, Rob Quinn, will take on the outgoing David Ellam’s responsibilities for the time being whilst a permanent successor is found
director leaving office
CEO David Horn Solomon wished Ellam all the best for the future

The chief financial officer of Silence Therapeutics PLC (LON:SLN), David Ellam, has left the gene editing specialist with immediate effect.

Silence’s group head of financial planning and analysis, Rob Quinn, will take on Ellam’s responsibilities for the time being whilst a permanent successor is found.

READ: Silence adds new siRNA asset to pre-clinical pipeline

“On behalf of the board I would like to thank David for his contribution to Silence,” said chief executive David Horn Solomon.

“He has played an important role in building the business and placing Silence Therapeutics in a strong position to continue the development of its product pipeline in the RNAi medicines space. We wish David every success for the future.”

View full SLN profile View Profile

Silence Therapeutics plc Timeline

Related Articles

scientists in a lab
January 30 2019
The technology first drew the attention of ChemioCare CEO Pedro Lichtinger years ago while he oversaw Pfizer's global primary care business
consumer health segment overview
January 11 2019
The company sells clinically validated anti-ageing products for hair, skin and body.
bacteria
December 17 2018
Summit has big plans for its flagship ridinilazole C. Diff treatment as well as its gonorrhoea and hospital superbug candidates this year, and it now has the funds to develop all of them as intended

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use